Pulmonx Corporation Common Stock (LUNG) — Analysis Summary
Pulmonx Corporation Common Stock (LUNG) has a market cap of $49.42M with year-over-year revenue growth of +8.0%. Net margin stands at -59.7%. The stock trades at a P/E ratio of -0.9.
Key Takeaways
- Revenue changed +8.0% year-over-year
- Net margin of -59.7%
- P/E ratio of -0.9
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, LUNG posted revenue growth of +8.0% and trades at a P/E of -0.9.
Pulmonx Corporation Common Stock (LUNG)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -15.5x — earnings do not cover interest payments
Operating margin at -58.8% — severe operating losses
Net margin at -60.1% — significant losses
The latest filing shows negative free cash flow.
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
296
Headquarters
REDWOOD CITY, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.